Skip to main content
. Author manuscript; available in PMC: 2015 Apr 9.
Published in final edited form as: Curr Opin Organ Transplant. 2013 Dec;18(6):672–681. doi: 10.1097/MOT.0000000000000029

Table 2.

Registered clinical trials of MSC in solid organ transplantation (ClinicalTrials.gov)

NCT* Title Site Settings Type of MSC MSC Inoculum Type of Study Start Date
00646724 graphic file with name nihms-597419-t0002.jpg Cotransplantation of islet and mesenchymal stem cell in Type 1 diabetic patients Fuzhou, China Islet Transplant UC-MSC 1-2 × 106/kg bw simultaneous islet and MSC transplantation via hepatic portal vein Interventional Safety/Efficacy Single Group Assignment Open Label Jan 2008
00658073 graphic file with name nihms-597419-t0003.jpg Induction therapy with autologous mesenchymal stem cells for kidney allografts Fuzhou, China Living Donor Kidney Transplant Autologous BM-MSC 1-2 × 106/kg bw, IV at reperfusion and day14 Interventional Randomized Safety/Efficacy Parallel Assignment Open Label Mar 2008
00659620 graphic file with name nihms-597419-t0004.jpg Mesenchymal stem cell transplantation in the treatment of chronic allograft nephropathy Fuzhou, China Chronic Kidney Rejection Autologous BM-MSC 1-2 × 106/kg bw, IV once a week for 4 weeks (total 4 injections) Interventional Safety/Efficacy Single Group Assignment Open Label May 2008
00734396 graphic file with name nihms-597419-t0005.jpg Mesenchymal stem cells and subclinical rejection Leiden, Netherland Kidney Rejection Autologous BM-MSC 106/kg bw, IV 7 days apart (total 2 injections) Interventional Non-Randomized Safety/Efficacy Single Group Assignment Open Label Feb 2009
00752479 graphic file with name nihms-597419-t0006.jpg Mesenchymal stem cells under Basiliximab/low dose RATG to induce renal transplant tolerance Bergamo, Italy Living Donor Kidney Transplant Autologous BM-MSC 2×106/kg bw IV Interventional Randomized Safety/Efficacy Parallel Assignment Open Label May 2008
01175655 graphic file with name nihms-597419-t0007.jpg A study to evaluate the potential of mesenchymal stromal cells to treat obliterative bronchiolitis after lung transplantation Chermside, Australia Lung Transplant HLA identical and allogeneic (Third-party) BM-MSC ? 2×106/kg bw IV, twice weekly, 2 wks Interventional Single Group Assignment Safety/Efficacy Open Label Feb 2010
01429038 graphic file with name nihms-597419-t0008.jpg Mesenchymal stem cells after renal or liver transplantation Liege, Belgium Liver or Kidney Transplant Allogeneic (Third-party) BM-MSC 1.3-3.0×106/kg bw day 3±2 Interventional Non-Randomized Safety/Efficacy Parallel Assignment Open Label Feb 2012
01668576 graphic file with name nihms-597419-t0009.jpg Properties of mesenchymal stem cells in lung transplant candidates Atlanta, USA Lung Transplant Autologous BM-MSC In vitro assessment only Observational Cohort Cross-sectional Aug 2012
01690247 graphic file with name nihms-597419-t0010.jpg Human mesenchymal stem cells induce liver transplant tolerance Beijing, China Liver Transplant UC-MSC 106/kg bw IV once every 4 weeks day 0 to 12 weeks Interventional Randomized Safety/Efficacy Parallel Assignment Open Label Feb 2012

Status: Inline graphic Recruiting Inline graphic Completed Inline graphic Unknown

*

Abbreviations: BM: Bone Marrow; bw: body weight; HLA: Human Leukocyte Antigen; IV: intravenous; MSC: Mesenchymal Stromal (stem) Cell; NCT: CLinicaTrial.gov Identifier; UC: Umbilical Cord